These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 1355734)
1. Comparison of the effects of efaroxan and glibenclamide on plasma glucose and insulin levels in rats. Berridge TL; Doxey JC; Roach AG Eur J Pharmacol; 1992 Mar; 213(2):213-8. PubMed ID: 1355734 [TBL] [Abstract][Full Text] [Related]
2. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists. Abdel-Zaher AO; Ahmed IT; El-Koussi AD Pharmacol Res; 2001 Nov; 44(5):397-409. PubMed ID: 11712871 [TBL] [Abstract][Full Text] [Related]
3. alpha2A-adrenoceptor antagonism increases insulin secretion and synergistically augments the insulinotropic effect of glibenclamide in mice. Fagerholm V; Scheinin M; Haaparanta M Br J Pharmacol; 2008 Jul; 154(6):1287-96. PubMed ID: 18493247 [TBL] [Abstract][Full Text] [Related]
4. Interactions between imidazoline compounds and sulphonylureas in the regulation of insulin secretion. Mourtada M; Brown CA; Smith SA; Piercy V; Chan SL; Morgan NG Br J Pharmacol; 1997 Jun; 121(4):799-805. PubMed ID: 9208151 [TBL] [Abstract][Full Text] [Related]
5. Selectivity profile of the alpha 2-adrenoceptor antagonist efaroxan in relation to plasma glucose and insulin levels in the rat. Berridge TL; Doxey JC; Roach AG; Smith CF Eur J Pharmacol; 1992 Mar; 213(2):205-12. PubMed ID: 1355733 [TBL] [Abstract][Full Text] [Related]
6. Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080. Brown CA; Chan SL; Stillings MR; Smith SA; Morgan NG Br J Pharmacol; 1993 Nov; 110(3):1017-22. PubMed ID: 7905338 [TBL] [Abstract][Full Text] [Related]
7. The alpha 2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cells. Chan SL; Dunne MJ; Stillings MR; Morgan NG Eur J Pharmacol; 1991 Oct; 204(1):41-8. PubMed ID: 1687123 [TBL] [Abstract][Full Text] [Related]
8. Potentiation of Glibenclamide Hypoglycaemia in Mice by MK-467, a Peripherally Acting Alpha2-Adrenoceptor Antagonist. Ruohonen ST; Ranta-Panula V; Bastman S; Chrusciel P; Scheinin M; Streng T Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):392-8. PubMed ID: 26132275 [TBL] [Abstract][Full Text] [Related]
9. The alpha 2-adrenoceptor antagonist, (+)-efaroxan, enhances acetylcholine release in the rat cortex in vivo. Tellez S; Colpaert F; Marien M Eur J Pharmacol; 1995 Apr; 277(1):113-6. PubMed ID: 7635166 [TBL] [Abstract][Full Text] [Related]
10. Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan. Chan SL; Mourtada M; Morgan NG Diabetes; 2001 Feb; 50(2):340-7. PubMed ID: 11272145 [TBL] [Abstract][Full Text] [Related]
11. Stimulation of insulin secretion by the imidazoline alpha 2-adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding site. Chan SL; Brown CA; Morgan NG Eur J Pharmacol; 1993 Jan; 230(3):375-8. PubMed ID: 8095024 [TBL] [Abstract][Full Text] [Related]
12. Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. Chan SL; Morgan NG Eur J Pharmacol; 1990 Jan; 176(1):97-101. PubMed ID: 2178947 [TBL] [Abstract][Full Text] [Related]
13. Studies on the dynamics and mechanism of glibenclamide-induced insulin secretion. Basabe JC; Farina JM; Chieri RA Horm Metab Res; 1976 Nov; 8(6):413-9. PubMed ID: 12072 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of antihyperglycaemic action of efaroxan in mice: time for reappraisal of α2A-adrenergic antagonism in the treatment of type 2 diabetes? Lehner Z; Stadlbauer K; Adorjan I; Rustenbeck I; Belz M; Fenzl A; de Cillia VA; Gruber D; Bauer L; Frobel K; Brunmair B; Luger A; Fürnsinn C Diabetologia; 2012 Nov; 55(11):3071-82. PubMed ID: 22898767 [TBL] [Abstract][Full Text] [Related]
16. Drug-induced desensitization of insulinotropic actions of sulfonylureas. Ball AJ; McCluskey JT; Flatt PR; McClenaghan NH Biochem Biophys Res Commun; 2000 Apr; 271(1):234-9. PubMed ID: 10777708 [TBL] [Abstract][Full Text] [Related]
17. Effects of dexmedetomidine and MK-467 on plasma glucose, insulin and glucagon in a glibenclamide-induced canine hypoglycaemia model. Kallio-Kujala IJ; Bennett RC; Raekallio MR; Yatkin E; Meierjohann A; Savontaus E; Scheinin M; Spillmann T; Vainio OM Vet J; 2018 Dec; 242():33-38. PubMed ID: 30503541 [TBL] [Abstract][Full Text] [Related]
18. The role of alpha- and beta-adrenoceptor subtypes in mediating the effects of catecholamines on fasting glucose and insulin concentrations in the rat. John GW; Doxey JC; Walter DS; Reid JL Br J Pharmacol; 1990 Aug; 100(4):699-704. PubMed ID: 1976400 [TBL] [Abstract][Full Text] [Related]
19. Effects of the imidazoline ligands efaroxan and KU14R on blood glucose homeostasis in the mouse. Mayer G; Taberner PV Eur J Pharmacol; 2002 Nov; 454(1):95-102. PubMed ID: 12409010 [TBL] [Abstract][Full Text] [Related]
20. Essential role of the imidazoline moiety in the insulinotropic effect but not the KATP channel-blocking effect of imidazolines; a comparison of the effects of efaroxan and its imidazole analogue, KU14R. Bleck C; Wienbergen A; Rustenbeck I Diabetologia; 2005 Dec; 48(12):2567-75. PubMed ID: 16283242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]